Bronchiectasis Position Statement

Despite its low profile, bronchiectasis is a common condition and remains a major contributor to chronic respiratory morbidity in less-affluent populations, both indigenous and non-indigenous. Correct diagnosis of bronchiectasis can be delayed by years or even decades in both children and adults, and it is likely that many remain undiagnosed and untreated, putting these people at risk of premature and accelerated pulmonary decline.

With recent advances in the management of bronchiectasis patients have new options in terms of diagnostics, antibiotic therapy and physiotherapy. While the principles of management may not have changed, some new but simple interventions mean that patients who receive an early and accurate diagnosis can most likely experience improved quality of life and health outcomes.

A position statement from the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia on Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand is provided below.

Position statement on Bronchiectasis from TSANZ and ALF (454 KB)

 

Sponsors

The COPD National Program receives unrestricted sponsorship towards the development of training and resources from the following companies:

 

Foundation Partners:
Principal Partners:

Novartis Pharmaceuticals

AZ Logo 150px
Supporting Partners: GlaxoSmithKline.